BR112022022761A2 - Inibidor de sos1 contendo fósforo - Google Patents
Inibidor de sos1 contendo fósforoInfo
- Publication number
- BR112022022761A2 BR112022022761A2 BR112022022761A BR112022022761A BR112022022761A2 BR 112022022761 A2 BR112022022761 A2 BR 112022022761A2 BR 112022022761 A BR112022022761 A BR 112022022761A BR 112022022761 A BR112022022761 A BR 112022022761A BR 112022022761 A2 BR112022022761 A2 BR 112022022761A2
- Authority
- BR
- Brazil
- Prior art keywords
- sos1
- containing phosphorus
- inhibitor containing
- sos1 inhibitor
- relates
- Prior art date
Links
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title abstract 3
- 229940126271 SOS1 inhibitor Drugs 0.000 title abstract 3
- 229910052698 phosphorus Inorganic materials 0.000 title abstract 3
- 239000011574 phosphorus Substances 0.000 title abstract 3
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract 2
- 102000057028 SOS1 Human genes 0.000 abstract 2
- 108700022176 SOS1 Proteins 0.000 abstract 2
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract 2
- 101150100839 Sos1 gene Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
INIBIDOR DE SOS1 CONTENDO FÓSFORO. O presente pedido refere-se ao campo da química farmacêutica, refere-se a um inibidor de SOS1 contendo fósforo, isto é, um composto de fórmula (I) e um método de preparação para o mesmo, e uma composição farmacêutica que contém o composto e refere-se ao seu uso na preparação de uma droga para o tratamento de uma doença e/ou distúrbio relacionado a SOS1 ou regulado por SOS1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010387620 | 2020-05-09 | ||
CN202110450032 | 2021-04-25 | ||
PCT/CN2021/092672 WO2021228028A1 (zh) | 2020-05-09 | 2021-05-10 | 含磷的sos1抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022022761A2 true BR112022022761A2 (pt) | 2023-02-14 |
Family
ID=78525260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022022761A BR112022022761A2 (pt) | 2020-05-09 | 2021-05-10 | Inibidor de sos1 contendo fósforo |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4148056A4 (pt) |
JP (1) | JP2023524864A (pt) |
KR (1) | KR20230095878A (pt) |
CN (1) | CN115461342A (pt) |
AU (1) | AU2021271381A1 (pt) |
BR (1) | BR112022022761A2 (pt) |
CA (1) | CA3182745A1 (pt) |
IL (1) | IL298050A (pt) |
MX (1) | MX2022013974A (pt) |
TW (1) | TW202144352A (pt) |
WO (1) | WO2021228028A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114685487B (zh) * | 2020-12-27 | 2024-04-19 | 上海凌达生物医药有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
CN114716478A (zh) * | 2021-01-07 | 2022-07-08 | 武汉人福创新药物研发中心有限公司 | 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途 |
WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
JP2024514127A (ja) | 2021-04-09 | 2024-03-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗がん剤療法 |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
WO2023134374A1 (zh) * | 2022-01-12 | 2023-07-20 | 如东凌达生物医药科技有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
KR20230121208A (ko) * | 2022-02-10 | 2023-08-18 | (주)파로스아이바이오 | Sos1 억제제 및 이의 유도체 |
CN117304182A (zh) * | 2022-06-22 | 2023-12-29 | 上海海和药物研究开发股份有限公司 | 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用 |
WO2024056782A1 (en) * | 2022-09-16 | 2024-03-21 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
WO2024079252A1 (en) | 2022-10-13 | 2024-04-18 | Bayer Aktiengesellschaft | Sos1 inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003299943A1 (en) * | 2002-12-23 | 2004-07-22 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
EP3878850A1 (en) * | 2016-12-22 | 2021-09-15 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
EP3601267A1 (en) * | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
EP3781565A1 (en) * | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
EP4074317A1 (en) * | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
-
2021
- 2021-05-10 KR KR1020227043479A patent/KR20230095878A/ko active Search and Examination
- 2021-05-10 TW TW110116832A patent/TW202144352A/zh unknown
- 2021-05-10 BR BR112022022761A patent/BR112022022761A2/pt unknown
- 2021-05-10 JP JP2022568428A patent/JP2023524864A/ja active Pending
- 2021-05-10 WO PCT/CN2021/092672 patent/WO2021228028A1/zh active Application Filing
- 2021-05-10 IL IL298050A patent/IL298050A/en unknown
- 2021-05-10 CN CN202180030884.3A patent/CN115461342A/zh active Pending
- 2021-05-10 CA CA3182745A patent/CA3182745A1/en active Pending
- 2021-05-10 AU AU2021271381A patent/AU2021271381A1/en active Pending
- 2021-05-10 EP EP21804515.1A patent/EP4148056A4/en active Pending
- 2021-05-10 MX MX2022013974A patent/MX2022013974A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022013974A (es) | 2023-01-11 |
EP4148056A4 (en) | 2024-05-29 |
AU2021271381A1 (en) | 2023-01-19 |
IL298050A (en) | 2023-01-01 |
CN115461342A (zh) | 2022-12-09 |
KR20230095878A (ko) | 2023-06-29 |
CA3182745A1 (en) | 2021-11-18 |
EP4148056A1 (en) | 2023-03-15 |
WO2021228028A1 (zh) | 2021-11-18 |
TW202144352A (zh) | 2021-12-01 |
JP2023524864A (ja) | 2023-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022022761A2 (pt) | Inibidor de sos1 contendo fósforo | |
BRPI0713367A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
BRPI0706992C1 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
AR065135A1 (es) | Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
BR112022023271A2 (pt) | Compostos | |
BR112016005271A2 (pt) | Moduladores de canais de sódio para o tratamento da dor e do diabetes | |
BR112017018643A2 (pt) | "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas" | |
BR112015022092A8 (pt) | derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo | |
BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
BR112018001035A2 (pt) | compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos | |
BR112015029897A2 (pt) | composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição | |
BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
BRPI0607258A2 (pt) | uso, composto, bem como formulações farmacêuticas | |
AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
BRPI0808353B8 (pt) | usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados |